Adrenal disease

Differences in α-Blockade Practices Between Endocrine and Surgical Specialties for Pheochromocytoma and Paraganglioma Resection: A Single-Center Retrospective Study

Endocr PractPublished Retrospective cohort study

Authors' conclusion

Despite differences in α-blockade strategies between the groups, perioperative hemodynamic outcomes were comparable, supporting flexibility in management. Tumor burden and patient age were associated with perioperative hemodynamic variability.

Study context

Population
Patients with PPGL undergoing laparoscopic or robot-assisted resection, 2006–2023, single academic center
Participants
78 patients
Exposure
Preoperative α-blockade by endocrine vs surgical specialties
  • Endocrinen = 28
  • Surgicaln = 50reference
Outcome
Perioperative outcomes
Methodological detailslongitudinal, single-centre
  • Longitudinal
  • Single-centre

Main finding

As reported in the abstract

Perioperative hemodynamic outcomes
  • Perioperative hemodynamic outcomes remained comparable between groups

Observational data: associations, not effects.

Further findings

Duration of α-blockade

Dose of selective α-blockers

Dose of nonselective α-blockers

Daily α-blocker administration frequency

Higher frequency of daily α-blocker administration in Endocrine vs Surgical

Predictors of hypotension (overall cohort)

Larger tumor size and higher metanephrine concentrations associated with both systolic and diastolic hypotension
P < 0.05 for both

Predictors of prolonged systolic BP >160 mmHg (overall cohort)

Elevated metanephrine levels and older age correlated with prolonged duration of systolic BP >160 mmHg
P < 0.05

Original publication

Differences in α-Blockade Practices Between Endocrine and Surgical Specialties for Pheochromocytoma and Paraganglioma Resection: A Single-Center Retrospective Study. Endocr Pract. Published 12 September 2025. doi:10.1016/j.eprac.2025.09.006

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.